Use of marizomib for the treatment of central nervous system (CNS) cancers
US10894036B2 · kind B2 · utility
0Cited by
11References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 1, 2017 |
| Grant date | Jan 19, 2021 |
| Priority date | — |
| Expiry date | Aug 14, 2037 |
Classification
- Technology area (CPC —)General
Abstract
The present disclosure relates to treatment of central nervous system (CNS) cancers (e.g., malignant glioma, glioblastoma, or CNS-multiple myeloma) using marizomib. The disclosure further relates to uses of synergistic combinations of marizomib with additional therapeutic agents such as bevacizumab, daratumumab, temozolomide, pomalidomide, and radiotherapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.